IMCD N.V. (IMCD) Earnings Call Transcript
November 5, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the conference call on IMCD's first nine months of 2026 results. I'm joined today by our CEO, Marcus Jordan, and our CFO, Hans Kooijmans. <<operator_script>> At this point I'll hand things over to Marcus Jordan. Mr. Jordan, the floor is yours.
Thanks, Alba. Good morning, everyone, and a warm welcome to you all. My name is Marcus Jordan, and joining me today is our CFO, Hans Kooijmans, for the 2026 first 9 months results, which we released in a press release earlier this morning. Before we move on to discuss the results, I'd like to take this opportunity to note that this is a very special call, as not only is this the last earnings call with Hans, who will retire at the end of this year, but it is also Hans' 50th earnings call. I think we all agree this is quite a remarkable milestone. As announced in December last year, Hans will be succeeded by Floris Lagerwerf, and I would like to take this opportunity to thank Hans very much for the smooth transition this year, and I'm looking forward to working even more closely together with Floris going forward. Now moving on to the first 9 months results, we have had a good year so far with both gross profit and EBITA organic growth and a strong cash conversion. When looking at the overall business, I'm proud of how our teams have navigated through the dynamic environment and focused on the commercial and operational topics, which we can control with the primary aim of getting even closer to our customers and suppliers.
Our partners clearly need us today more than they ever have, and from a customer standpoint we see that need in, say, how many formulatory projects are moving through our technical centers or labs, along with the opportunity pipeline that gets built and converted as a result. Customers keep ordering just-in-time as well, and our job is making sure the correct inventory sits in place to meet those requirements. On the supplier side, we remain focused on delivering what we promised when it comes to business simplification, market intelligence, formulatory expertise and growth. As I said on our previous call, we also have a healthy pipeline of new supplier projects, and some nice wins are coming to fruition. Turning to our suppliers, as we also discussed last call, in the second quarter of this year we saw the majority of them putting price increases in place. Those increases differed a great deal in magnitude, with the larger specialty portion of the portfolio generally getting much lower percentage increases and displaying less volatility than our smaller semi-specialty components. During the third quarter, although some price movement remained, pricing has generally been far more stable, with what I would call more normal behavior.
From a demand standpoint, this steadier picture also holds true, and ordering frequency hasn't shown any meaningful variation as far as we can tell. Looking across the different markets we serve, our Pharmaceutical and Food & Nutrition segments remain resilient and continue to perform well. Within Beauty & Personal Care, demand is generally flat to rising compared with last year. We keep concentrating on this area, since the technical capabilities and lab infrastructure we possess present solid opportunities. There are also some encouraging trends in this market, such as K-Beauty in Korea, where we recently completed 2 acquisitions: YCAM, which closed last year, and Dang Yong FT, which closed in January this year. Turning to the industrial side, the fairest characterization of our business over the first 9 months is positive, with several bright pockets in areas like medical plastics, lubricants, and wire and cable for data centers. Now to the 2026 first 9 months figures. A summary of our financial results appears on Slide 4, where we reported gross profit of EUR 991 million, up 9% on a constant currency basis. EBITA rose to EUR 425 million, which is plus 11% on a constant currency basis.
Free cash flow came in at EUR 317 million, and that gave us a cash conversion margin of 73%. That shows how carefully we watch working capital while, as I said before, making sure the right inventory is on hand to serve our customers. When times are as unpredictable as they are now, it matters even more that we keep sales activity at its highest level, adjust quickly when market conditions shift, and stay a dependable partner for customers and suppliers alike. Our focus will remain on what we can control, and we are committed to long-term growth for our partners and stakeholders in the years to come. Turning to what lies ahead, the fourth quarter is still young, but I can tell you we have gotten off to a promising start. As this morning's press release sets out in the outlook we published, we anticipate organic operating EBITA growth this year. To sum up and close the introduction on my side, I think we have executed well across the first 9 months of the year, and I see solid traction in the commercial, operational and digital excellence initiatives we have concentrated on, among them continued supply development and expansion.
At this point, I’d like to turn things over to Hans Kooijmans, our CFO, for an update on the numbers.
I appreciate the kind words, Marcus, and good morning, everyone. You're correct — this is my 50th analyst call. Along with the numerous other investor meetings and discussions I've had over the years, it has been a genuine pleasure keeping you informed about how IMCD is developing. I'm especially glad that the tone of this call, like that of our more recent ones, is significantly more upbeat than it was roughly 1.5 years ago. That shift in tone isn't merely a matter of sentiment — it comes through clearly in the figures shown on Page 6 of today's analyst call presentation. All together, these developments point to a clear and positive trend, highlighting the resilience of IMCD's business model and confirming that we're heading in the right direction to once again build a strong foundation for sustainable organic growth in the years to come. As you can see on Page 6, ForEx adjusted revenue and gross profit each rose, by 10% and 9% respectively, versus last year. That 9% organic gross profit growth was a combination of 4% organic and 5% from the positive impact of acquisitions being included for the first time.
Those businesses we bought recently carried, on average, gross profit margins a touch below IMCD's. Because of that, the group's overall gross profit margin slipped slightly, landing at 25%. Strip out the effect of those recent acquisitions, though, and the gross profit percentage for 2026 would actually have come in a bit above the 25.2% recorded across the first 9 months of last year. Turning to organic gross profit growth across the first 3 quarters, you may recall IMCD posted minus 4% organic in Q1, followed by plus 7% in Q2, and this quarter brought plus 10% organic growth. Overall, that makes for a positive trend as the year progressed. This organic gross profit growth, paired with tight cost control, produced a comparable result at the operating EBITA level. The reported 11% ForEx adjusted increase to EUR 425 million came from 5% organic growth and 6% from M&A. As Marcus noted, organic EBITA growth in the third quarter reached 14%, with every segment delivering organic EBITA growth. Our year-to-date conversion margin edged up 0.4 percent points to 42.9%, and we also report a very healthy free cash flow of EUR 317 million.
I'll return to cash flow on a later slide. As a result, net result went up, and earnings per share rose as well, both by 20% on a ForEx-adjusted basis. Cash earnings per share increased by EUR 0.57 in absolute terms, which was a bit above the EUR 0.52 rise in earnings per share. Overall, these are solid growth figures. The count of full-time employees was slightly lower than in September 2025, but bear in mind that the year-to-date 2026 figures include an extra 150 new employees coming from the acquisitions completed over the last 12 months. Moving on, Slide 7 on the next page gives you a summary of several key figures broken out by regional operating segment. This slide is quite crowded with numbers, and I could imagine Floris and Tosca reformatting it next year. Tosca is confirming to me that she will. Looking across the columns, EMEA and APAC results are clearly satisfactory, with positive organic growth on every line in the high single digits or even low double digits, together with acquisition growth in the high single digits.
So those healthy growth figures meant we could lift our EBITA margin and conversion ratio in both EMEA and APAC. In the Americas, though, the result is disappointing — a really weak first quarter of 2026, with organic EBITA growth at minus 25%. As you may recall, the two quarters that followed, in which we posted modest organic gross profit and modest EBITA growth, were not enough to offset that number. This is definitely a segment we are working hard to improve. And in the holding companies column, we show a cost base slightly below the same period of last year. Moving to Page 8, a summary of IMCD's free cash flow. The absolute free cash flow amount came in EUR 33 million above last year, with a cash conversion ratio of 73%. In my view, that is an acceptable number for a third quarter with 6% organic top line growth. The main driver of the improvement was higher operating EBITA. Working capital investment was more or less similar to last year, with increased stock and debtor positions the most important drivers of the investment. At quarter end, we held a relatively high stock position to cater for the strong Q4 order book.
Those increased debtor balances came about because sales were strong during the quarter. We feel confident that, at year-end, we will report a cash conversion ratio in the neighborhood of the high 80% or a low 90% figure. Next, on Page 9, there is an update regarding net debt and leverage. Net debt as of the end of September stood at approximately EUR 1.5 billion, a bit below the end of December. The reported leverage ratio, which includes the full year impact of acquisitions, as is customary, came in at 2.6x EBITDA, and that is comparable to the leverage calculated under the definitions in our loan documentation. Then, last but not least, on Page 10, our outlook for 2026 can be found. And, as Marcus already said, you can read there that we anticipate organic operating EBITDA growth in this year. I would like to pass things to Alba, the operator, so the lines can be opened for Q&A.
<<operator_script>> Our initial question is from Anil Shenoy of Barclays.
To start, Hans, congratulations on your 50th earnings call. Working with you has been a pleasure, and I wish you the best in whatever comes next.
Thanks.
I have just a couple of questions for you. Yes—so, two from my side. The first concerns your medium- to long-term view on organic growth. My thinking here is that over the past 5 years, organic growth has been quite extreme—very high in '21 and '22, then moderating across the following 3 years. Prior to that, gross profit organic growth ran at roughly the 6% level. So looking ahead, over the medium to long term, is there any reason to believe—has anything changed during the last 5 years that would suggest this 6% gross profit figure cannot be reached, or that it can? This is particularly relevant given that your competitor recently put out, sort of, a midterm target of—mid- to high single digits on gross profit and high single digit on EBITA. So I'm very keen to hear your thinking on medium- to long-term organic growth. And my second question concerns the M&A pipeline. Your leverage has clearly come down, now to 2.6x from 2.8x at the end of 2025. That leaves you with a significant runway for acquisitions. So how should we think about your acquisition strategy over the next 12 months?
With the leverage ratio now sitting comfortably under your 3x target, should we expect an acceleration? Essentially, how will acquisitions over the next 9 months compare with what we saw in the last 12 months?
Anil, to start with your first question about organic growth over the medium to long term. As you mentioned, we previously guided that figure at roughly 6% to 7% organic gross profit growth year-over-year. Naturally, across an extended stretch, I believe we remain quite at ease saying that. When you consider the industry drivers, and we've discussed on many occasions items such as consolidation, outsourcing, and the rationalization by suppliers regarding how many distributors they work with. Every one of those, I'd argue, business fundamentals remain firmly in place. So we're comfortable with the historical guidance we've provided. And naturally, as the company's critical mass expands and the business model essentially gains from scale. So we likewise hold the ambition for the conversion margin to rise. Regarding the mergers and acquisitions pipeline, we're quite pleased, I'd say, to have the firepower we now possess with the ratio of 2.6x. We have, I'd say, a healthy pipeline of projects. As I noted on the previous call, a few of those discussions are perhaps taking somewhat longer than they would have in the past. Super important for us, as it has always been, to stay laser-focused on really only pursuing targets where we see a very good fit, which we see as able to accelerate organic growth for the long-term future, and not be in a rush to close deals.
And yes, I'd say we're quite optimistic about the discussions we currently have underway.
Our next question is a follow-up from Suhasini Varanasi at Goldman Sachs.
Best of luck going forward, Hans. On trading, I just want to clarify whether you have observed organic GP growth shift significantly during the quarter, or any changes in September or October. Also, what does the order book look like right now for the next 4 weeks? Second, regarding Americas, I would like to get a sense of the growth momentum there. It seems somewhat more lackluster than the other regions. Do you see any performance differences between the U.S. and LatAm, and are particular verticals weighing on the business there?
Suhasini, first off, regarding organic GP growth and how orders came in, I'd say there's nothing significant to report when it comes to shifts during the quarter. I believe I've covered as much as I want to regarding the outlook, where once again we've gotten off to a promising start in the fourth quarter. On the growth momentum in the Americas, as Hans said earlier, we've been quite candid that this is an area requiring improvement. Also, as I noted on the previous call, we've lately bolstered the management team we have there. I have to say I'm very happy with the changes we've implemented, and we're cautiously optimistic about the region's future. I think if you also examine how the region has performed and look back across the years, historically this region has done extremely well. And in many years, it actually beat both the EMEA and the APAC region. So there's also a bit of a comp topic to keep in mind there. And we've also noted previously that especially from a North America standpoint, we carry somewhat more industrial exposure, things like coatings and construction, where generally we've seen somewhat weaker demand for the reasons we all know, and LatAm being more volatile in general.
That said, especially given the adjustments we've put in place lately, we're feeling a fair amount of optimism about what lies ahead in that area.
Annelies Vermeulen of Morgan Stanley has our next question.
Hans, two questions from me, if I may. First, on pricing: at the H1, you mentioned that pricing had been strong in Q2 but had softened as the quarter went on. I believe you also noted earlier that Q3 has shown pricing behavior that's more normal. That said, we've clearly also seen a lot of volatility in oil prices and input costs, and so on, during the quarter. So could you comment on what you've observed on pricing through Q3, and in particular, whether you think there's room for it to pick up again perhaps as we head into Q4 and into next year? Then second, on customer behavior: Marcus, I think in your opening remarks you said you haven't seen any shift in order frequency. So can we take from that that we're still seeing, sort of, more frequent orders, and that this hasn't changed? But given the hopefully improving backdrop, do you think that will shift into next year? Or do you think this is actually the new norm when it comes to customer behavior?
Thanks, Annelies. Regarding pricing, yes, it's really gone back to what I'd call a more typical pattern, where certain suppliers keep raising prices. Overall, though, I'd describe it as considerably steadier. We obviously don't know yet how things will look ahead. But as usual in our industry, a number of product lines face greater pricing pressure than others. And with crude staying at a fairly elevated level, it wouldn't shock me if suppliers start passing some further price increases through at the start of the new year. Still, we'll have to wait and see. But yes, on the whole, I'd call it more typical pricing behavior. When it comes to customer behavior, yes, I'd say there's no genuine shift in how often orders come in or in the quantities involved. As you're aware, we don't tend to focus much on quantity, since our emphasis is heavily on the specialty side. What's evident, however, is that customers continue to need and ask for just-in-time deliveries. And my sense is this could persist well into the future. I also think customers have altered how they act, given that they've grown to depend on us delivering that level of performance.
And since we operate as a distributor, that's actually something we appreciate, because it's the service we provide, and we view it as one of their capabilities.
Got it. As a quick follow-up on that point: you mentioned more just-in-time deliveries along with greater order frequency — does that carry any extra cost implications? Or do you feel the business is now properly set up to handle that going forward?
The way this is structured works really well, thanks to the global ERP platform we have in place. We can see our costs right away. So when logistics costs shift, or a customer needs a smaller quantity — clearly, per kilo or per gram, the freight cost relative to that goes up — we spot it right away and pass it through.
Got it, Marcus, thank you. And Hans, I want to wish you all the best, and thanks for being so engaged with us.
I appreciate that.
Our following question is from Matthew Yates of Bank of America.
Sorry, it feels as though the day has dragged on already given how many results we've seen. Hans, once more, I'll simply repeat what others have said. Thank you for all your assistance through the years. A few questions, if I may. I'm certain you know that Azelis recently recorded a very sizable write-down since numerous deals they completed aren't projected to hit their hurdle rates. I won't ask you to weigh in on how other people allocate capital. But looking at IMCD, could you remind me of the internal process you follow when conducting impairment tests, and whether any deals from your past might need their assumptions revisited? And looking ahead, are there learnings that could alter how you screen targets or integrate them, so that the strategy keeps delivering? I heard Marcus's earlier remark about, sort of, that laser focus, but I'd like to discuss the impairment process a bit. Then my second question concerns headcount and costs — you indicated that, sort of, the underlying headcount fell by roughly 150 this year. If you do believe we're now back to a sustainable sort of growth algorithm, how should we think about cost and headcount going forward?
And perhaps this connects to a few of your digital efforts. Do you believe there's still room there to generate additional productivity that could help support operating leverage down the road?
Marcus, I believe I should address the impairment question. Matthew, if you — the process itself is fairly straightforward. When a triggering event occurs, you have to act right away. Internally, we follow a somewhat formal routine, and certainly each quarter we hold that discussion among ourselves. Then annually, we carry out a more structured exercise in which, first, we request input on the parameters that ought to be applied for impairment testing. Second, as our base input, we rely on the current year's estimate, next year's budget, the 2 planned years beyond that, and what we refer to as terminal growth rates. We're currently midway through that exercise, working from preliminary results. It's fair to say we anticipate no impairments there. If you consider how we've behaved over the years, looking at the parameters we apply — the most important being the pretax WACC and the terminal growth rates — I think we adopt a far more conservative stance than most peers in the industry. That also suggests we're somewhat more robust in that respect.
Also, though this is harder to assess—as Marcus already pointed out—we tend to be quite disciplined about the prices we pay for acquisitions and very cautious in how we value them. That certainly helps us steer clear of large impairment tests as well. So we'll watch how things go, but I'm fairly optimistic. Then, on your question about individual companies: when I look at how the businesses we've bought have performed, I'd say it's fair to note there's always some variability between what we expect and what actually happens. Still, on balance, I'd call the result quite favorable. And that's another reason you won't find impairment problems on our side. Turning to costs, Marcus, would you like to address that?
Yes.
My view is that it's moving ahead.
Yes. Matthew, if I consider headcount and costs moving forward, what I'd say is that when we examine our current initiatives, certainly the short term is a period where, broadly speaking, we remain quite cautious about bringing on more people. At the same time, though, we want to ensure we truly put money behind everything we're doing from a commercial excellence standpoint. That means really pushing sales activity and making sure we're in front of customers as much as possible, and so not being afraid to put investment into, let's say, the frontline commercial teams, whether those sit out on the road or work from an inside sales angle. Naturally, we're also putting substantial investment in from an AI angle to explore how we can enhance operational excellence and how we can enhance customer service. And once again, that's mainly driven right now by how we can become even more effective. We do expect efficiency gains, but I think those will come more from a longer-term viewpoint.
Our following question is from Nicole Manion at UBS.
Best wishes to you, Hans. I have two questions, if I may. First, going back to the Americas, you clearly discussed the softer results there and the management changes you've implemented. Do you believe additional investment in that business will be needed as we head into next year? How are you thinking about that? Or which areas are you still, sort of, examining for improvement? Second, in Q2 you mentioned picking up some share in semi specialties as Asian supply grew less reliable in certain markets. Have you kept seeing that in Q3? Is it still affecting performance? Or has there been some kind of, I suppose, normalization there?
Thank you, Nicole. When it comes to the Americas, I wouldn’t point to anything particular in the way of extra investments being needed. What it really comes down to, I’d say, is reinforcing our current efforts from the standpoint of commercial excellence. And I apologize, but that question about the semi specialties side doesn’t really register with me. Yes, it forms part of our business, yet measured against the entire portfolio, it’s fairly small. It’s a meaningful piece. Still, as with all that we do, we examine the full portfolio throughout every one of the business lines and units, asking how we can close gaps in the product portfolio. That applies from both a specialty and a semi-specialty angle. That said, I’d tell you there’s nothing particular to report on the semi-specialty side. Does that address your question, or?
Yes. Sorry, perhaps I could frame that another way. I believe there was some commentary in Q2 suggesting that certain Asian supply had grown somewhat less secure, and that type of situation, sort of, temporarily eased off, though maybe you anticipated that kind of Asian competitive pressure would, sort of, return at some stage. I'm just curious whether you're still seeing that. Yes.
Yeah, I'd put it as being, once again, that term stable — we really haven't observed much movement from Q2 into Q3. So competition in China is certainly present, though I wouldn't characterize anything as a major shift across those 2 quarters.
Yes. Understood. That's helpful.
Luuk Van Beek of Degroof Petercam has the next question.
Let me start with a question about Asia Pacific, since you put up quite a strong performance there. Was there anything in particular that drove those results? And second, your operating costs came in a bit higher. I'd imagine bonus accruals also had an impact. Could you speak to what drove the costs in Q3?
Thanks, Luuk. Yeah, looking across APAC, I'd describe it as pretty consistently strong when you go market by market. So there isn't really anything particular I'd single out beyond that, generally speaking. I'd say the IMCD teams have done very well on both commercial excellence and operational excellence. And yeah, I'd call it solid execution with good demand. As for the bonus accrual, Hans, I think it's fair to say that from a cost standpoint, we do like to reward our people when performance is good. So I think you'll notice a difference there between last year and this one.
Alright. Is there any way you can give us a sense of what the impact might be?
Yeah. That’s a tough one, Luuk. But the numbers we’re discussing aren’t substantial. When you look at the increase in our own costs that we’ve reported year-to-date, I’d say net-net it’s a very low single-digit figure. And that’s also reflected in the fact that our conversion margin is improving both year-to-date and in the quarter versus last year. It does have an impact. And typically, with your bonus pool, what you see is that it starts building up during the year. And last year, because of the disappointing outcome we had during the year, there were releases here and there. That difference is something we need to make good additional margin on, and we hope we do.
Up next, we have a question from David Symonds at BNP Paribas.
I believe I only have one question, if that's alright. It concerned the pharma business. Perhaps I'm overthinking the wording, but it sounds as though pharma has shifted from green shoots to being resilient now. And when I look at APAC performance in Q3, top-line organic growth looks similar to Q2, yet organic growth is considerably stronger further down the P&L in gross profit and EBITA — admittedly against a weak comp. So might I ask about what's happening in the pharma business, perhaps specifically Signet in India and how things are evolving there?
David, as I believe you're aware, pharma stands out among our market segments for how reliably it performs and expands. If you remember, we hit a somewhat turbulent stretch late last year owing to tariffs. That created a modest drag in Q4, if my memory serves. You could say the pharma business is now back at its customary performance level. And we're pleased with what I'd call the more usual growth we've seen throughout this year. Naturally, that takes in the Signet business as well.
Understood. Thanks, and I wish you the best of luck going forward, Hans.
Quirijn Mulder from ING has the next question.
Yes, Hans, first off, thank you for your service. I have never come across a CFO as consistent as you are. So many thanks for everything, for the last 10 years. My question concerns especially the U.S., the discussion we had regarding the coast-to-coast story. How is that progressing? And when can we see the first benefits of that taking place? Because the U.S. is still -- it's positive on EBITA and on gross profit, but it is not yet very strong. And maybe some more elaboration on Latin America, how the developments are there? Those were my questions.
Thank you, Quirijn. Yeah, I mean, obviously you can't see it, but we're already starting to see the coast-to-coast developments reflected in how many suppliers we now genuinely represent across the whole country. That figure is rising quite substantially. As I believe I've said previously, in certain cases that means parting ways with some suppliers that either aren't willing, or that don't represent a solid strategic fit, for working with us on a coast-to-coast basis. Occasionally there can also be somewhat of a timing effect there. And you can imagine that might be happening right now in 1 or 2 cases. But yes, overall we're happy with the traction that the coast-to-coast model has generated. It's hard for me to state precisely when those numbers will start to come through. But behind the scenes, we're putting in hard work on that. The traction is good, and I'm optimistic about the future.
What about Latin America?
Could you repeat the Latin America question? My apologies, Quirijn.
Yeah. So how would you characterize the competitive landscape? Would you say it’s coming back? I mean, last year the Chinese were pretty aggressive in selling products across Latin America. So what’s the situation like there now? Has it gotten better? Or would you say the Chinese are still coming back, now that the impact of the Strait of Hormuz has slowed somewhat?
Yeah. Like I told Nicole earlier, there hasn't been a big shift on that front from Q2 to Q3. So it's fair to say, obviously, that Chinese competition exists. But I'd say no dramatic difference between the last 2 quarters.
Our following question is from David Kerstens at Jefferies.
Hans, to start, thanks so much for everything you've done to help us over the years, and I wish you the very best in your retirement.
Thanks.
Was EMEA's somewhat soft momentum during Q3 mostly a function of a tougher comparison? I believe you mentioned in Q2 that the 10% was largely the result of mandate wins. So I was curious how mandate wins trended in Q3. And second, given more normal pricing, does that imply you're also seeing prices decline from the recent peaks? Hans, I think you've said before that over the past 30 years you've never witnessed prices falling. What does this year look like on that front?
Thanks for the questions. On EMEA performance, once more, what I'd say is that it's generally being driven by solid results across the majority of countries. Mandate wins have played a part in that, but I wouldn't call them the dominant factor by any stretch. It's genuinely a mix of several different elements. As for normal pricing, I believe what I wasn't talking about there is pricing declining. What I meant is that we aren't experiencing dramatic pricing swings, and also that pricing, especially in the specialty portfolio, continues to hold up well. It's fair to say that broadly we have not observed price cuts, particularly over the past couple of quarters. That normal pricing behavior is more about, I'd say, stability, along with certain product lines still trending upward. But it's really on a product-by-product basis rather than a broad movement.
Our last question is from Eric Wilmer at Van Lanschot Kempen.
You flagged, I think, a really solid beginning to the quarter. Would you say that's a fair reflection of what you saw across regions and sectors in Q3? Or are there other regions or sectors that might be picking up which had been somewhat softer until lately? Maybe on M&A — since product pricing seems to be normalizing, as you mentioned — could you comment on how willing potential targets are to look through perhaps part of this year, particularly a strong Q2? I can imagine that sets things up for potential targets to extrapolate a strong Q2 and possibly Q3? One last question — I know it's still early days, but given what happened 2 days ago in the U.S., what kind of effect could something like that have on business sentiment? I think it's a broad question, but the reason I'm asking is that tariff uncertainty has been one of the main drivers so often cited behind weak business confidence, particularly in Europe.
Alright, regarding how the fourth quarter has begun — like we mentioned, it's an encouraging start. I wouldn't point to any specific market or country shifting compared with how things went for us in the second quarter from a performance standpoint. So there's nothing material to report on that front. When it comes to M&A targets, as Hans mentioned, we conduct extremely thorough due diligence as we work through really evaluating how a potential target fits, and we're quite careful about what that company's profitability is today and what we think it will be down the road. As you know, we've safeguarded ourselves previously and will keep doing that through certain mechanisms if our view of what the future holds differs from the seller's. So I'd say we keep monitoring, tracking, and holding discussions with M&A targets just as we always have. But as you noted, with a careful approach regarding what profitability will look like going forward. On the election's impact — yes, it's very hard to say right now. But I think something we do really well as a company is focusing on what we can control, things such as commercial and operational excellence, and maintaining our flexibility and agility.
My sense is that the asset-light model is a real advantage for us in this situation. Still, we have a highly active sales and commercial group that examines each opportunity available to us, and that is essentially the full extent of what we can do. Tariffs are outside our control — we can't influence what happens on that front — but I think we should stay very alert and keep listening closely, then tweak and adapt whenever the need arises.
That's useful. And Hans, congratulations on reaching such a significant milestone, plus many thanks for the really enjoyable collaboration.
Yes. Thank you, Eric. And before Marcus closes, I'd also like to use this moment to express my thanks to all of you — for your ongoing interest in IMCD, for all your kind questions, for the feedback you've given, and above all, for the constructive dialogue we've shared over the years. Working with you has always been a pleasure. I also want to wish Floris every success as he takes over from me. Most of you know him well by now, and I have great, great confidence that he'll keep building on the relationships we've established together. And finally, looking ahead, I believe IMCD is excellently positioned to seize the opportunities in front of us. As you know, we've built a resilient business model. We've put together a very strong team, and we've also regained commercial momentum. There's still a lot of potential to unlock, and I'm confident that IMCD has the right foundations, the right people and also the right strategy to deliver sustainable and profitable growth in the years ahead. A big thank you to you all, and back to Marcus.
Thanks so much, Hans, for all those calls through the years. Hosting some of them alongside you has truly been a pleasure and a privilege for me. I appreciate your incredible contribution, the insights you brought, and the wonderful collaboration throughout. And to everyone on the call, thanks for being with us this morning and for your questions — enjoy the rest of your day. Many thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IMCD N.V. transcript - plus 131,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IMCD N.V. earnings transcripts and 131,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.